Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,539.39
(
-0.80%
)
US TECH 100
23,246.40
(
-1.13%
)
Dow Jones
46,265.54
(
-0.35%
)
Brent Oil
102.24
(
3.50%
)
Bitcoin
68,898.00
(
-3.37%
)
News Focus
News Focus
Post# of 257293
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Mpower

Send PM Follow Ignore
Followers 2
Posts 635
Boards Moderated 0
Alias Born 04/23/2007

Mpower

Re: randychub post# 105055

Saturday, 09/25/2010 11:37:37 AM

Saturday, September 25, 2010 11:37:37 AM

Post# of 257293
No. Copaxone approval is not a limiting factor to "ink deals for other biologics." Sandoz/NVS seems to think MNTA is worth something....

"George says that partner Momenta Pharmaceuticals technical abilities in characterizing complex sugar molecules was key to getting the approval. Momenta’s technology “is highly differentiated and certainly played a significant role.”" (see http://blogs.forbes.com/sciencebiz/2010/07/26/novartis-honcho-golden-age-of-generic-biotech-drugs-is-coming/)
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today